Format

Send to

Choose Destination
Hum Vaccin Immunother. 2016 Jul 2;12(7):1766-76. doi: 10.1080/21645515.2015.1135279. Epub 2016 Feb 2.

Current and future effects of varicella and herpes zoster vaccination in Germany - Insights from a mathematical model in a country with universal varicella vaccination.

Author information

1
a ESME - Epidemiological and Statistical Methods Research Group, Helmholtz Centre for Infection Research , Braunschweig , Germany.
2
b PhD Programme "Epidemiology" Helmholtz Centre for Infection Research/Hannover Medical School , Braunschweig/Hannover , Germany .
3
c German Center for Infection Research (DZIF) , Hannover-Braunschweig site , Germany.
4
d Department of Health Economics and Health Care Management , School of Public Health, Bielefeld University , Bielefeld , Germany.
5
e Julius Centre for Health Sciences & Primary Care, University Medical Centre Utrecht , Utrecht , The Netherlands.
6
f Centre for Infectious Disease Control, RIVM , Bilthoven , The Netherlands.
7
g Immunization Unit, Robert Koch Institute , Berlin , Germany.
8
h Institute of Virology, Department of Medical Microbiology and Hygiene, University Medical Center , Freiburg , Germany.
9
i Hannover Medical School , Hannover , Germany.

Abstract

Varicella zoster virus (VZV) is primarily known for causing varicella in childhood, but can reactivate again as herpes zoster (HZ) after a period of latency, mainly in persons older than 50 years. Universal varicella vaccination was introduced in Germany in 2004, while HZ vaccination has not been recommended yet. We aimed to quantify the potential long-term effects of universal childhood varicella vaccination and HZ vaccination of the elderly on varicella and HZ incidence in Germany over a time horizon of 100 years, using a transmission model calibrated to pre-vaccination data and validated against early post-vaccination data. Using current vaccination coverage rates of 87% (64%) with one (two) varicella vaccine dose(s), the model predicts a decrease in varicella cases by 89% for the year 2015. In the long run, the incidence reduction will stabilize at about 70%. Under the assumption of the boosting hypothesis of improved HZ protection caused by exposure to VZV, the model predicts a temporary increase in HZ incidence of up to 20% for around 50 years. HZ vaccination of the elderly with an assumed coverage of 20% has only limited effects in counteracting this temporary increase in HZ incidence. However, HZ incidence is shown to decrease in the long-term by 58% as vaccinated individuals get older and finally reach age-classes with originally high HZ incidence. Despite substantial uncertainties around several key variables, the model's results provide valuable insights that support decision-making regarding national VZV vaccination strategies.

KEYWORDS:

herpes zoster; transmission model; uncertainty; varicella; varicella vaccination; zoster vaccination

PMID:
26835890
PMCID:
PMC4964823
DOI:
10.1080/21645515.2015.1135279
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Taylor & Francis Icon for PubMed Central
Loading ...
Support Center